{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"From fragile skin to living medicine: Lessons from RDEB","slug":"from-fragile-skin-to-living-medicine-lessons-from-rdeb","published_at":"2026-06-18T14:03:31+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/from-fragile-skin-to-living-medicine-lessons-from-rdeb","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/7aa1c95d27d40b37390516f5787556880ff8488c150539e74e530b5b34670c2e/eyJlcGlzb2RlSWQiOiIyY2RiNzZhNC02NmRjLTRiZDMtYWQyNC0zMGU5NzcyMGE0NTMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEzM2ZhZTRmYjZmOGQ4M2VmYTFkYzdkL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTE4X18xNi00LTIwLm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/7aa1c95d27d40b37390516f5787556880ff8488c150539e74e530b5b34670c2e/eyJlcGlzb2RlSWQiOiIyY2RiNzZhNC02NmRjLTRiZDMtYWQyNC0zMGU5NzcyMGE0NTMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEzM2ZhZTRmYjZmOGQ4M2VmYTFkYzdkL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTE4X18xNi00LTIwLm1wMyJ9.mp3","summary":"In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Mark Lowdell , CSO & Co-Founder, INmuneBio Inc Vishwas Seshadri , CEO & Director, Abeona Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona The…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1303,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/from-fragile-skin-to-living-medicine-lessons-from-rdeb/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/from-fragile-skin-to-living-medicine-lessons-from-rdeb.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}